Biosergen AB
STO:BIOSGN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biosergen AB
Operating Expenses
Biosergen AB
Operating Expenses Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Expenses | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biosergen AB
STO:BIOSGN
|
Operating Expenses
-kr26.8m
|
CAGR 3-Years
-63%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Biogaia AB
STO:BIOG B
|
Operating Expenses
-kr676.6m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
Bonesupport Holding AB
STO:BONEX
|
Operating Expenses
-kr855.7m
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-26%
|
CAGR 10-Years
N/A
|
|
|
Vitrolife AB
STO:VITR
|
Operating Expenses
-kr1.4B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-29%
|
CAGR 10-Years
-19%
|
|
|
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
|
Operating Expenses
-kr14.2B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
-23%
|
|
|
BioArctic AB
STO:BIOA B
|
Operating Expenses
-kr681.1m
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-40%
|
CAGR 10-Years
N/A
|
|
Biosergen AB
Glance View
Biosergen AB operates as a biopharmaceutical company. The company is headquartered in Solna, Stockholm. The company went IPO on 2021-06-24. The company carries out biopharmaceutical research and development through its Subsidiary Biosergen AS from laboratory facilities in Trondheim, Norway and several other places worldwide. The firm is developing BSG005, a potentially disruptive antifungal drug which has demonstrated safety and potency advantages over competing antifungals. Biosergen initially aims BSG005 towards invasive fungal infections that claim the lives of hundreds of thousands of immune-compromised AIDS, cancer and transplant patients every year. At equal dose levels BSG005 has demonstrated a three-to-fouold potency advantage against the relevant fungal strains compared to the current standard of care, while being completely free of the kidney toxicity hampering other drugs in its class.
See Also
What is Biosergen AB's Operating Expenses?
Operating Expenses
-26.8m
SEK
Based on the financial report for Dec 31, 2023, Biosergen AB's Operating Expenses amounts to -26.8m SEK.
What is Biosergen AB's Operating Expenses growth rate?
Operating Expenses CAGR 3Y
-63%
Over the last year, the Operating Expenses growth was 21%. The average annual Operating Expenses growth rates for Biosergen AB have been -63% over the past three years .
